Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a report published on Friday,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent BioSolutions’ Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $1.04 EPS, Q3 […]
HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a report published on Friday,Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Emergent BioSolutions’ Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $1.04 EPS, Q3 […]
